Although there was no direct evidence to indicate the molecular mechanism of PNPLA3 inhibition in gout, based on previous studies of PNPLA3 and our MR results, we speculated that PNPLA3 inhibition leads to LD accumulation, thereby disrupting LD remodeling and triggering mitochondrial dysfunction, excessive ROS, and lipid peroxidation products [6, 30, 31]. The gene discussed is NR3C2; the disease is gout.